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analysis. Infection density rate (IDR), conditional maximum
likelihood estimate (CMLE) of rate ratio (RR), 95% con-
ﬁdence intervals (CI), and P values were calculated. The Fisher
exact test was used to compare IDRs among years. P< .05 was
considered statistically signiﬁcant.
The IDR did not increase for ESBL-EC after cessation of
contact precautions in our hospital. Also, no change was
observed for IDR for ESBL-producing K. pneumoniae or for
CR K. pneumoniae between 2015 and 2016. An increase in CR
E. coli bacteremia at the Oncology Hospital was observed, but
it was not statistically signiﬁcant (Table 1).
A recent Swiss study showed the safety of cessation of con-
tact precautions for ESBL-EC in a setting where compliance
with standard infection control precautions and hand hygiene
is high.5 Compliance with infection control precaution is
highly variable in our hospital. The rate of compliance with
hand hygiene before patient contact is nearly 90% in the
oncology ICU and BMT units; however, it was 30%–60% in
the surgical ICUs. Nevertheless, we did not observe an increase
in the rate of ESBL-EC bacteremia.
This study has some limitations. First, we did not compare
the types of ESBL-EC infection other than bacteremia between
2015 and 2016, but no clusters of ESBL-EC infections were
detected in any of the wards during surveillance activities.
Bacteremia surveillance is the only type of surveillance that is
performed hospital-wide, so we decided to compare the
bacteremia rates. Also, we did not have access the molecular
epidemiology of ESBL-EC because it is very difﬁcult to analyze
the genetic relatedness of ESBL-EC in daily practice for
infection control purposes.
Despite all limitations, our study showed that, in a middle
outcome country where compliance to infection control pre-
caution is highly variable, cessation of contact precautions
for ESBL-EC did not result in a negative outcome. However,
infection control teams practicing in crowded hospitals under
high workload with insufﬁcient staff should be cautious
because ESBL-EC outbreaks are common.
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ICD-9-CM Coding for Multidrug Resistant
Infection Correlates Poorly With
Microbiologically Conﬁrmed Multidrug
Resistant Infection
To the Editor—The International Classiﬁcation of Diseases,
Ninth revision, Clinical Modiﬁcation (ICD-9-CM) coding
system is often used to conduct surveillance for various
infections.1 Unfortunately, ICD-9-CM coding is subject to
error and does not always reﬂect the true level of comorbid and
acute illnesses.2 Little research has been done to determine the
accuracy of ICD-9-CM codes to identify multidrug-resistant
organism (MDRO) infections.3 Inaccurate coding of MDROs
has implications for monitoring of MDRO transmission
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dynamics, assessments of MDRO epidemiology, calculations
of hospital ratings and rankings, and hospital reimbursements.
At present, no globally utilized MDRO reporting system exists.
Therefore, understanding the sensitivity of ICD-9-CM codes
for various MDROs will inform policy decisions regarding
hospital rankings and reimbursements and determine the
limitations of ICD-9-CM codes for studying MDRO infections
from large retrospective administrative databases. Our goal
was to determine the correlation between microbiologically
conﬁrmed MDRO infection in sterile sites or bronchial wash/
bronchoalveolar lavage (BAL) cultures and ICD-9-CM coding
for various MDROs.
This study was conducted at Barnes-Jewish Hospital, a
1,250-bed academic medical center in St Louis, Missouri. The
study period was January 1, 2006, to October 1, 2015. Hospi-
talized patients with a positive sterile site or BAL/bronchial
wash culture for any of the following MDROs were identiﬁed
from the hospital clinical data repository and assessed for
eligibility: Enterobacteriaceae, Enterococcus spp., Staphylococcus
aureus, Pseudomonas aeruginosa, or Acinetobacter spp. Anti-
microbial susceptibilities were determined in the clinical
microbiology laboratory using disc diffusion methodology,
and drug resistance was deﬁned according to accepted deﬁni-
tions.4–6 Sterile sites were deﬁned as bloodstream; pleural,
intra-abdominal, pericardial, cerebrospinal, and synovial
ﬂuids; bone marrow; and surgical specimens collected from
lymph nodes, central nervous system, liver, spleen, kidney,
pancreas, ovary, or vascular tissue. This study was approved
with a waiver of informed consent by the Washington Uni-
versity School of Medicine Institutional Review Board.
All discharge ICD-9-CM diagnosis codes from the index
MDRO hospitalization were utilized. Medical coders can
assign an ICD-9-CM code for an organism and add a V09 code
if drug resistance is present. V09 codes were used to identify
drug resistance for all organisms except methicillin-resistant S.
aureus (MRSA) after October 1, 2008, when unique MRSA
codes were introduced.
The primary end points were the proportion of patients
with clinically identiﬁed MDROs who had a discharge ICD-9-
CM code for the correct organism and the proportion of
patients with a discharge ICD-9-CM code for drug resistance.
We also examined whether infectious disease (ID) consulta-
tion was associated with higher rates of coding for drug
resistance.
In total, 4,429 patients met the eligibility criteria. Patients
with MDR S. aureus that were not MRSA and with poly-
microbial MDRO infections were excluded, leaving 4,005
patients for analysis. MRSA patients were analyzed in 2 groups:
(1) patients discharged prior to October 1, 2008, and (2)
patients discharged after introduction of MRSA-speciﬁc
ICD-9-CM codes on October 1, 2008. Rates of organism and
drug resistance ICD-9-CM coding are shown in Table 1.
Patients with MRSA infections after introduction of the
MRSA-speciﬁc ICD-9-CM codes had high rates of appro-
priately coded organism (75.0%) and MDRO status (75.7%).
The proportion of MRSA patients with any drug resistance
code increased from 33.3% to 75.7% after the introduction of
MRSA-speciﬁc codes. Among patients surviving ≥48 hours
after cultures were drawn, ID consultation was associated with
a higher rate of coding for MRSA (519 of 587, 88.4%) than
for patients without ID consultation (306 of 474, 64.6%;
P < .001).
Patients with drug-resistant P. aeruginosa had the next
highest rate of appropriately coded organism (74.5%) but low
rates of drug resistance codes (8.3%). Drug-resistance coding
was poor for all non-MRSA pathogens, ranging from
table 1. Organism and Multidrug-Resistant Organism (MDRO) Discharge International Classiﬁcation of Diseases, Ninth Revision, Clinical
Modiﬁcation (ICD-9-CM) Codes for Various Sterile Site MDRO Infections
Drug-Resistant
Organism (No.)
Coded for Correct
Organism, No. (%)a
Any MDRO Code,
No. (%)b
Any
V09 Code,
No. (%)
Any V098, V0981, V099,
V0991 Code, No. (%)c
MRSA after 10/1/2008 (1,113) 835 (75.0) 843 (75.7) 39 (3.5) 10 (0.9)
MRSA before 10/1/2008 (504) 300 (59.5) 168 (33.3) 168 (33.3) 0
VRE (735) 209 (29.4) 169 (23.0) 162 (22.0) 24 (3.3)
Enterococcus (851) 242 (28.4) 172 (20.2) 164 (19.3) 24 (2.8)
Enterobacteriaceae (1226) 802 (65.4) 41 (3.3) 26 (2.1) 6 (0.5)
Acinetobacter spp. (107) 31 (29.0) 12 (11.2) 9 (8.4) 3 (2.8)
Pseudomonas aeruginosa (204) 152 (74.5) 17 (8.3) 10 (4.9) 6 (2.9)
NOTE. MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant Enterococcus.
aFor MRSA after 10/1/2008: 038.12, 482.42, 041.12. For MRSA before 10/1/2008: 038.11, 482.41, 041.11. For VRE and Enterococcus: 041.04. For
Enterobacteriaceae: 038.4, 038.40, 038.42, 038.44, 038.49, 041.3, 041.4, 041.49, 041.6, 041.85, 48.20, 48.282, 48.283. For Acinetobacter spp.:
038.40, 038.49, 482.83. For Pseudomonas aeruginosa: 038.43, 041.7, 48.21.
bAny of the following: 038.12, 482.42, 041.12 (MRSA codes); V09, V09.0, V09.1, V09.2, V09.3, V09.4, V09.5, V09.50, V09.51, V09.6, V09.7,
V09.71, V09.70, V09.8, V09.80, V09.81, V09.9, V09.91, V09.90.
cA distinction was made for V098, V0981, V099, and V0991 because these code for multidrug resistance, rather than single drug or single class
resistance of the other V09 codes.
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3.3% (Enterobacteriaceae) to 23.0% (vancomycin-resistant
Enterococcus) (Table 1).
The correlation between microbiologically conﬁrmed non-
MRSA MDRO infection and V09 diagnosis codes for drug
resistance was poor. Previous research showed poor correla-
tion between V09 codes and conﬁrmed MRSA infection prior
to the introduction of MRSA-speciﬁc ICD-9-CM codes.3 Our
MRSA coding rates after the introduction of MRSA-speciﬁc
ICD-9-CM codes were higher than previously reported.7 We
also found that ID consultation increased rates of MRSA
coding, likely due to increased recognition and documentation
of the presence and importance of MRSA by ID physicians.
In addition, coding rates for MRSA were signiﬁcantly higher
than coding rates of drug resistance for other organisms, sug-
gesting a need for unique codes for other MDROs. This con-
clusion is reinforced by the fact that for patients with MRSA,
introduction of MRSA-speciﬁc codes resulted in a dramatic
increase in coding for resistant S. aureus. As ICD-9-CM codes
are assigned by nonmedical personnel, universal drug resis-
tance deﬁnitions and organism-speciﬁc drug resistance codes
will likely assist in the proper coding of MDROs. Our ﬁndings
are likely applicable to ICD-10-CM codes because the struc-
ture of ICD-10-CM drug resistance codes mimics those from
ICD-9-CM.
Our results demonstrate that ICD-9-CM diagnosis codes
cannot be used to estimate the burden of MDRO infections in
hospitals. Additionally, researchers should be aware of the
limitations of ICD-9-CM codes for studying MDRO infections
from large retrospective medical databases. More speciﬁc
MDRO codes are needed to facilitate future research using
administrative data, a problem not addressed by ICD-10-CM.
To our knowledge, this study is the ﬁrst to examine drug
resistance coding rates for a variety of MDRO pathogens. The
study is limited to a single tertiary-care referral center, and
these results may not be generalizable. However, the study
draws strength from its large sample size and has implications
for hospital rankings, reimbursements, and future MDRO
research utilizing large administrative databases.
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Clostridium difﬁcile RT 078/ST11: A Threat to
Community Population and Pigs Identiﬁed in
Elder Hospitalized Patients in Beijing, China
To the Editor—Clostridium difﬁcile ribotype (RT) 078 has been
known as the predominant strain in animals (swine and
cattle), and it has been increasingly identiﬁed in human
C. difﬁcile infection causing severe disease and increased
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